Sanara MedTech Inc.
Business
Sanara MedTech Inc. is a medical technology company that develops and commercializes technologies to improve clinical outcomes and reduce healthcare costs in surgical, chronic wound and skincare markets. It offers surgical and wound care products such as CellerateRX Surgical, BIASURGE, FORTIFY products, bone grafts like BiFORM and ALLOCYTE Plus, and a value‑based wound care program with Care Hub, an MSO network and a technology platform. The company operates through two reportable segments, Sanara Surgical and Tissue Health Plus (THP), and maintains in‑house R&D and partnerships. Its products and services are marketed primarily in the United States to hospitals, ambulatory surgical centers, physician offices, skilled nursing and home‑based care providers, via distributors, field sales representatives and payer or provider contracts.
Summary from filing dated 2025-03-25
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net Revenue | 103 | 87 | 65 | 46 | 24 | |
| Cost of goods sold | 8 | 8 | 8 | 6 | 2 | |
| Gross profit | 96 | 79 | 57 | 39 | 22 | |
| Selling, general and administrative | 79 | 72 | 57 | 46 | 28 | |
| Research and development | 5 | 3 | 4 | 3 | 558,704 | |
| Depreciation and amortization | 3 | 3 | 4 | 2 | 596,975 | |
| Change in fair value of earnout liabilities | — | −14,451 | — | — | — | |
| Asset impairment charges | 2 | — | — | — | — | |
| Total operating expenses | 88 | 77 | 61 | 52 | 29 | |
| Operating income | 7 | 1 | −4 | −13 | −7 | |
| Interest expense | −7 | −3 | −475,783 | — | −711 | |
| Share of losses from equity method investments | −952,466 | −90,007 | — | −379,633 | −616,927 | |
| Interest income | 3,672 | 21,978 | — | — | — | |
| Gain on disposal of property and equipment | 10,932 | — | — | — | — | |
| Total other income (expense) | −8 | −3 | −224,749 | −1 | −617,638 | |
| Net loss from continuing operations | −393,124 | −2 | — | — | — | |
| Net loss from discontinued operations (including asset impairment charge of $26,472,407 in 2025) (Note 3) | −37 | −8 | — | — | — | |
| Net loss | −38 | −10 | −4 | −8 | −8 | |
| Net loss attributable to noncontrolling interest from continuing operations | −5,441 | −3,224 | — | — | — | |
| Net loss attributable to noncontrolling interest from discontinued operations | — | −244,127 | — | — | — | |
| Less: Total net loss attributable to noncontrolling interest | −5,441 | −247,351 | −136,705 | −154,831 | −71,881 | |
| Net loss attributable to Sanara MedTech shareholders | −38 | −10 | −4 | −8 | −8 | |
| Continuing operations, basic | −0.05 | −0.23 | — | — | — | |
| Continuing operations, diluted | −0.05 | −0.23 | — | — | — | |
| Discontinued operations, basic | −4.31 | −0.91 | — | — | — | |
| Discontinued operations, diluted | −4.31 | −0.91 | — | — | — | |
| Net loss per share of common stock, basic | −4.36 | −1.14 | −0.52 | −1 | −1.08 | |
| Net loss per share of common stock, diluted | −4.36 | −1.14 | −0.52 | −1 | — | |
| Weighted average number of common shares outstanding, basic | 9 | 8 | 8 | 8 | 7 | |
| Weighted average number of common shares outstanding, diluted | 9 | 8 | 8 | 8 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-09-30 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash | 17 | 16 | 5 | — | 9 | |
| Inventory, net | 4 | 3 | 5 | — | 4 | |
| Convertible loan receivable | — | 1 | — | — | — | |
| Prepaid and other assets | 948,620 | 1 | 608,411 | — | 1 | |
| Current assets related to discontinued operations (Note 3) | 67,863 | 101,334 | — | — | — | |
| Total current assets | 34 | 33 | 19 | — | 21 | |
| Intangible assets, net | 19 | 23 | 45 | — | 32 | |
| Goodwill | 4 | 4 | 4 | — | 4 | |
| Investment in equity securities | 15 | 6 | 3 | — | 3 | |
| Right of use assets operating leases | 2 | 1 | 2 | 2 | 806,402 | |
| Property and equipment, net | 456,962 | 432,317 | 1 | — | 1 | |
| Long-term assets related to discontinued operations (Note 3) | — | 20 | — | — | — | |
| Total long-term assets | 39 | 55 | 55 | — | 40 | |
| Total assets | 73 | 88 | 74 | — | 61 | |
| Accrued bonuses and commissions | 12 | 10 | 8 | — | 8 | |
| Accrued royalties and expenses | 3 | 2 | 2 | — | 2 | |
| Earnout liabilities current | 235,001 | — | 1 | — | 1 | |
| Operating lease liabilities current | 353,229 | 358,687 | 361,185 | — | 313,933 | |
| Current liabilities related to discontinued operations (Note 3) | 1 | 1 | — | — | — | |
| Total current liabilities | 19 | 15 | 14 | — | 13 | |
| Long-term debt | 46 | 31 | 9 | — | — | |
| Earnout liabilities long-term | — | 748,001 | 3 | — | 6 | |
| Operating lease liabilities long-term | 2 | 1 | 2 | — | 505,291 | |
| Other long-term liabilities | 548,125 | 1 | 2 | — | — | |
| Total long-term liabilities | 48 | 34 | 16 | — | 7 | |
| Total liabilities | 67 | 49 | 29 | — | 19 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Common Stock: $0.001 par value, 20,000,000 shares authorized; 8,946,913 issued and outstanding as of December 31, 2025 and 8,753,773 issued and outstanding as of December 31, 2024 | 8,948 | 8,754 | 8,535 | — | 8,300 | |
| Additional paid-in capital | 81 | 77 | 73 | — | 65 | |
| Accumulated deficit | −75 | −38 | −28 | — | −23 | |
| Total Sanara MedTech shareholders equity | 6 | 39 | 45 | — | 42 | |
| Equity attributable to noncontrolling interest | −8,666 | −491,611 | −244,260 | — | −107,555 | |
| Total shareholders equity | 6 | 39 | 45 | — | 42 | |
| Total liabilities and shareholders equity | 73 | 88 | 74 | — | 61 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 4 | 5 | — | — | — | |
| Asset impairment charges | 28 | — | — | — | — | |
| Gain on disposal of property and equipment | −9,674 | — | — | — | 41 | |
| Credit loss expense | 509,233 | 624,448 | 202,941 | 280,000 | 51,536 | |
| Inventory obsolescence | 582,046 | 521,757 | 406,812 | 540,090 | 251,826 | |
| Share-based compensation | 5 | 4 | 3 | 3 | 3 | |
| Noncash lease expense | 525,372 | 547,297 | 342,972 | 263,518 | 174,955 | |
| Back-end fee | 780,312 | 358,086 | — | — | — | |
| Paid-in-kind interest | 2 | 838,965 | — | — | — | |
| Accretion of finance liabilities | 148,179 | 210,931 | 98,926 | — | — | |
| Amortization and write-off of debt issuance costs | 279,905 | 209,499 | 5,138 | — | — | |
| Change in fair value of earnout liabilities | — | −2 | — | — | — | |
| Accrued interest income | — | −21,978 | — | — | — | |
| Accounts receivable, net | −114,690 | −5 | −2 | −2 | −695,018 | |
| Accounts receivable related parties | 40,566 | −32,166 | 90,148 | −18,761 | −79,787 | |
| Inventory, net | −2 | 1 | −2 | −517,271 | −1 | |
| Prepaid and other assets | 123,515 | −515,496 | 496,200 | −159,592 | −305,501 | |
| Accounts payable | 813,999 | −424,318 | 531,380 | −301,966 | 166,903 | |
| Accounts payable related parties | −5,913 | −46,891 | 43,768 | −121,781 | −67,772 | |
| Accrued royalties and expenses | 292,195 | 574,189 | −739,645 | — | — | |
| Accrued bonuses and commissions | 2 | 3 | −81,513 | — | — | |
| Operating lease liabilities | −526,905 | −502,892 | −252,366 | −263,370 | −176,012 | |
| Net cash provided by (used in) operating activities | 7 | −23,784 | −3 | −6 | −5 | |
| Purchases of property and equipment | −5 | −205,848 | −265,246 | −147,015 | −171,867 | |
| Proceeds from disposal of property and equipment | 60,000 | — | 650 | 1,549 | — | |
| Purchases of intangible assets | −23,452 | −23,452 | — | −600,000 | −578,586 | |
| Investment in equity securities | −8 | −5 | — | −250,000 | −5 | |
| Convertible loan receivable | — | −1 | — | — | — | |
| CarePICS Acquisition | −2 | — | — | — | — | |
| Net cash used in investing activities | −15 | −7 | −10 | −4 | −5 | |
| Loan proceeds, net of debt issuance costs of $228,183 in 2025 and $1,160,740 in 2024 | 12 | 29 | 10 | — | — | |
| Pay off line of credit | — | −10 | — | — | −800,000 | |
| Pay off debt assumed in CarePICS Acquisition | −2 | — | — | — | — | |
| Equity offering net expenses | — | −75,000 | 911,371 | — | 29 | |
| Net settlement of equity-based awards | −546,994 | −125,205 | −135,794 | −407,346 | −442,525 | |
| Cash payment of finance and earnout liabilities | −937,000 | −2 | −822,795 | — | — | |
| Net cash provided by financing activities | 9 | 17 | 10 | −627,346 | 28 | |
| Net increase in cash | 700,562 | 11 | −4 | −10 | 18 | |
| Interest | 3 | 2 | 283,948 | 206 | 711 | |
| Taxes | 48,792 | 40,586 | — | — | — | |
| Non-monetary exchange to acquire intangible assets | 2 | — | — | — | — | |
| Conversion of note receivable into equity method investment | 1 | — | — | — | — | |
| Earnout liability generated by CarePICS Acquisition | 1 | — | 4 | 7 | — | |
| Right of use assets obtained in exchange for lease obligations | 1 | — | 2 | — | — |